Wellness & HRT in Houston

Overview

Wellness and hormone therapy

Wellness and hormone therapy is a category — not a single procedure. A 45-year-old Houston woman searching “hormone therapy” might need FDA-approved estradiol and progesterone, compounded pellets, thyroid optimization, testosterone for low libido, or a GLP-1 for weight gain that’s actually a perimenopause symptom. This hub’s job is to help her figure out which concern she has, then route her to the right treatment.

This page is organized by concern, not by molecule. Women’s HRT, men’s TRT, and GLP-1 weight loss get the deepest coverage because those are the three largest patient categories and the ones with the most unique-angle content to offer. Peptides, IV therapy, and thyroid optimization get brief, pointed sections — deeper blog posts on each are coming separately. The Texas regulatory framework for all of this changed materially in 2025 [24][25]. Know it before you book.

Categories

What this category actually is

Five distinct concerns drive most Houston wellness clinic visits.

Perimenopause and menopause — hot flashes, sleep disruption, mood changes, weight gain, low libido, vaginal dryness. Typically women 40–58. FDA-approved treatment is systemic or local estrogen ± progesterone; the compounded alternative is bioidentical pellets and creams.

Andropause and low testosterone in men — fatigue, low libido, erectile dysfunction, loss of muscle mass. Typically men 35–65. The Endocrine Society threshold is two morning fasting total testosterone levels below 300 ng/dL combined with symptoms [7] — a bar many Houston clinics don’t actually enforce.

Metabolic and weight — the GLP-1 category. Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound). FDA declared both off the shortage list in late 2024/early 2025 [14][15], which changed what’s legally available from compounding pharmacies.

Energy and “optimization” — peptides, IV drips, NAD+. Almost none of this category has strong evidence; much of it is no longer legally compoundable [21][22].

Thyroid — a legitimate medical concern better handled by an endocrinologist than a med spa.

The question that matters most: which concern do you have? A woman with perimenopausal fatigue who gets put on testosterone pellets and compounded semaglutide has solved neither problem, spent $5,000, and now has supraphysiologic testosterone levels plus GI side effects. The right answer was usually FDA-approved estradiol + progesterone and, if weight was still primary, Wegovy or Zepbound at manufacturer direct pricing [18][19].

Decision

Understanding what you actually need

A rough decision framework:

Multiple concerns can coexist. Legitimate practice sequences — treats the biggest driver first, watches response, layers in. Commercial practice stacks everything on day one.

Women

Hormone therapy for women

This is the deepest section because it’s the largest patient category and the most subject to both undertreatment (legitimate menopause symptoms dismissed by PCPs) and overtreatment (pellet clinics pushing supraphysiologic dosing).

What the WHI actually said

The 2002 Women’s Health Initiative publication caused a generation of women to be denied hormone therapy. The subsequent literature substantially revised that picture. The WHI 18-year extended follow-up (Manson et al., JAMA 2017) found no increase in all-cause, cardiovascular, or cancer mortality across 18 years in women randomized to conjugated equine estrogens alone or with medroxyprogesterone acetate, with a signal for reduced mortality in women aged 50–59 at initiation [1].

The 2022 Menopause Society Position Statement (formerly NAMS) formalized the timing hypothesis: for healthy women under 60 or within 10 years of menopause onset with bothersome vasomotor symptoms, the benefit-risk profile of systemic hormone therapy is favorable [2]. Initiating HRT in older women or long after menopause is where the original WHI risk signals were strongest.

Practical translation: most Houston women between 45 and 58 with significant symptoms are candidates for hormone therapy. The question is which form.

FDA-approved HRT — the evidence-strongest option

• Systemic estradiol — transdermal patches (Vivelle-Dot, Climara, Minivelle), gel (Divigel, Estrogel), spray (Evamist), oral tablets (Estrace). Transdermal preferred over oral — avoids first-pass liver metabolism, lower VTE risk.
• Micronized progesterone — oral Prometrium, 100–200 mg nightly. Required for any woman with a uterus taking systemic estrogen to prevent endometrial hyperplasia.
• Vaginal estrogen for GSM — Vagifem tablets, Estrace cream, Imvexxy inserts, Estring. Very low systemic absorption; appropriate even for many breast cancer survivors after oncology clearance. Underutilized in Houston.
• Combination products — Bijuva (estradiol + progesterone), Combipatch (estradiol + norethindrone).

Most insurance covers these products. Generic transdermal estradiol + generic micronized progesterone typically runs $20–$50/month after insurance — a fraction of pellet therapy cost with stronger evidence.

Compounded bioidentical hormone therapy — when legitimate, when marketing

The distinction Houston marketing blurs:

Legitimate compounded HRT — a woman with a documented allergy to an FDA-approved product’s excipient, a non-standard dose not made by any manufacturer, or a specific vaginal formulation (DHEA vaginal, estriol vaginal) not available as an FDA-approved product.

Commercial cBHT marketing — claims that “bioidentical” compounded hormones are safer or more “natural” than FDA-approved bioidentical products (estradiol is estradiol regardless of source). Claims that saliva testing guides dosing. Claims that pellets are superior to patches.

The NASEM 2020 report commissioned by FDA concluded compounded bioidentical therapy “lacks rigorous evidence of safety and effectiveness” [3]. Both the 2022 Menopause Society Position Statement [2] and ACOG recommend against routine cBHT when FDA-approved bioidentical products are available.

Pellet therapy — honest assessment

Pellet therapy — most visibly the BioTe franchise with 100+ Houston-area providers [29], plus non-franchised compounded-pellet practices — inserts testosterone and/or estradiol pellets subcutaneously every 3–4 months. Houston pricing: $350–$600 per insertion for women, $700–$1,500 for men, plus ~$150 annual consultation.

The real concerns:

• Supraphysiologic dosing. Pellet-delivered testosterone in women frequently produces serum levels 2–5× the physiologic female range (15–70 ng/dL), with documented risks of erythrocytosis, alopecia, acne, voice changes [4][30].
• Not adjustable. Once inserted, levels can’t be adjusted down for 3–4 months absent surgical excision.
• No large RCT evidence base. The pivotal menopause trials used oral and transdermal formulations.
• Most insurers classify as experimental and don’t cover [5].

A legitimately-used legal FDA-approved testosterone pellet exists for men (Testopel). Compounded pellets for women are not FDA-approved.

Men

Testosterone replacement therapy for men

Who qualifies

The Endocrine Society 2018 Clinical Practice Guideline [7] and AUA 2018 Testosterone Deficiency Guideline [8] both require:

1. Two morning (7–10 AM) fasting total testosterone measurements below 300 ng/dL, on separate days
2. Consistent symptoms (low libido, ED, fatigue, depressed mood, loss of muscle mass)
3. Secondary workup to identify reversible causes — obesity, sleep apnea, opioids, hyperprolactinemia

Many Houston “low T” clinics prescribe on a single lab — sometimes an afternoon draw where diurnal variation alone produces false “low” readings — or on symptoms alone. That’s below the standard of care. Symptoms alone don’t distinguish hypogonadism from depression, OSA, or ordinary aging.

The TRAVERSE trial update

TRAVERSE (Lincoff et al., NEJM 2023) randomized 5,246 hypogonadal men age 45–80 with cardiovascular disease or high CV risk to transdermal testosterone gel vs. placebo over mean 21.7 months [9]:

• Noninferior for major adverse cardiovascular events (MACE — CV death, nonfatal MI, nonfatal stroke)
• Significantly higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group

FDA updated testosterone labeling in 2025 to reflect these findings [10]. Practical translation: TRT in properly diagnosed hypogonadism is not the cardiovascular catastrophe earlier literature suggested — but it’s not risk-free, and “optimizing” testosterone in eugonadal men (normal levels) has no supportive trial evidence.

FDA-approved TRT forms

• Testosterone cypionate/enanthate IM injections — weekly or every 2 weeks, the most common Houston prescription. Generic, inexpensive.
• Transdermal gels — AndroGel, Testim, Fortesta, Vogelxo [11]
• Transdermal patches — Androderm
• Subcutaneous injection — Xyosted auto-injector, weekly
• Oral — Jatenzo (testosterone undecanoate), Tlando
• Nasal — Natesto
• Long-acting IM depot — Aveed (REMS program)
• Pellets — Testopel (FDA-approved for men; compounded pellets are not)

Testosterone is a Schedule III controlled substance — prescribers must hold DEA registration, and Texas further regulates dispensing.

Monitoring requirements

Legitimate TRT requires baseline and periodic labs: total testosterone, free testosterone, hematocrit/hemoglobin, PSA (in men 40+), estradiol, lipid panel. Hematocrit above 54% is the main dose-reduction trigger (erythrocytosis → thrombosis risk). PSA monitoring catches accelerated prostate cancer growth (TRT doesn’t cause it, but can unmask). Clinics that don’t draw baseline PSA, don’t recheck hematocrit quarterly in year one, or don’t measure estradiol are practicing below the standard.

Fertility-sparing options

Men who want to preserve fertility should not take exogenous testosterone (suppresses FSH/LH → testicular shutdown). Alternatives: hCG, clomiphene, or enclomiphene to stimulate endogenous production. Most Houston “T clinics” don’t discuss this; men who want kids need a urologist-led workup.

The “low T clinic” commercial model

Chains running cash-pay TRT at $99–$275/month with standard bundled protocols (weekly injections + anastrozole + HCG) often prescribe on a single lab, skip secondary workup, routinely co-prescribe anastrozole without clear estradiol indication, and minimize monitoring. The 2025 legal literature documents rising malpractice suits against low-T prescribers for polycythemia, stroke, MI, and infertility in men who were never documented hypogonadal [28]. Not every Houston TRT clinic operates this way — but enough do that the red flags below matter.

GLP-1

Medical weight loss and GLP-1s

FDA-approved products

• Semaglutide — Ozempic (T2DM), Wegovy (obesity/overweight with comorbidity). Once-weekly injection.
• Tirzepatide — Mounjaro (T2DM), Zepbound (obesity/overweight with comorbidity). Once-weekly dual GIP/GLP-1 agonist.

Expected results from pivotal trials

• STEP-1 (semaglutide, NEJM 2021) — mean 14.9% body-weight reduction at 68 weeks vs. 2.4% placebo. Roughly 34 lbs vs. 6 lbs in a 225-lb starting patient [12].
• SURMOUNT-1 (tirzepatide, NEJM 2022) — up to 22.5% body-weight reduction at 72 weeks on tirzepatide 15 mg. About 90% of participants lost at least 5% [13].

The lean mass problem

SURMOUNT-1 body-composition substudies show roughly 25% of weight lost is lean tissue (33.9% fat-mass reduction vs. 10.9% lean-mass reduction). Consequences: sarcopenic weight loss, facial volume loss (“Ozempic face”), and loose skin — all of which drive downstream consultations for body contouring modalities like Emsculpt Neo (muscle rebuild) and skin tightening. Legitimate programs bundle resistance training and protein intake protocols (1.2–1.6 g/kg/day) with prescriptions.

The 2024–2025 compounding enforcement story

From 2022–2024, FDA-declared shortages of semaglutide and tirzepatide permitted 503A and 503B pharmacies to compound these drugs. Thousands of Houston med spas and telehealth services prescribed compounded versions at $150–$400/month — a fraction of brand pricing. That window has essentially closed [14][15][17]:

• Tirzepatide off shortage: December 2024 [14]
• Semaglutide off shortage: February 2025 [15]
• 503B outsourcing facility wind-down: May 2025
• 503A patient-specific compounding: tightened guidance, active FDA enforcement [17]

What this means in Houston in April 2026: a clinic selling “compounded semaglutide” or “compounded tirzepatide” at commodity pricing without documented patient-specific clinical need is operating in a gray-to-illegal zone [16].

Manufacturer direct pricing (April 2026)

The arbitrage that drove compounding has collapsed:

• Zepbound (tirzepatide) via LillyDirect: $299/month (2.5 mg), $449/month (5–15 mg) [18]
• Wegovy (semaglutide) via NovoCare Pharmacy: $349/month self-pay ($199 intro for first 2 low-dose fills) [19]
• Insurance coverage remains inconsistent; weight-loss indications have patchy coverage with prior auth

Houston legitimate programs (example: Huemn) now run $99–$500/month for manufacturer-sourced product plus clinical services — body composition scans, coaching, lab tracking [20].

Contraindications

Don’t take GLP-1s with: personal or family history of medullary thyroid cancer or MEN2; pregnancy or planning pregnancy; severe gastroparesis; active pancreatitis history. Watch for acute pancreatitis, cholelithiasis, gastroparesis, volume depletion/AKI, and — the under-discussed one — depression/suicidality signals under post-marketing review. Perioperative holds are required for surgery [32].

Peptides

Peptides

In September 2023, FDA added 19 peptides to Category 2 of the 503A interim bulks list [21]. Category 2 means “do not compound.” These include:

BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, GHK-Cu (injectable), melanotan II, kisspeptin-10, epitalon, ibutamoren and others.

A September 2024 settlement forced FDA to refer five peptides (CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604, Selank) to the Pharmacy Compounding Advisory Committee. The PCAC voted against 503A inclusion at both October and December 2024 meetings [22].

What this means for Houston clinics in 2026: most “peptide stacks” being sold — BPC-157 injections, CJC/ipamorelin combinations, “longevity protocols” — are dispensing unapproved new drugs outside any off-label framework. There is no legal protection for the prescriber.

What remains legal:

• Sermorelin (not Category 2) — can be compounded in limited circumstances.
• Tesamorelin (Egrifta) — FDA-approved for HIV-associated lipodystrophy only.
• Research chemicals sold online “not for human use” cannot be legally injected into humans in the US.

IV Therapy

IV therapy and NAD+

What has evidence: IV iron for documented refractory iron-deficiency anemia, IV hydration for severe dehydration, IV B12 for pernicious anemia — all in appropriate clinical settings, not med spas.

What doesn’t: “Myers cocktail,” glutathione IV, NAD+ IV, “beauty drips,” “hangover drips.” The evidence base is dominated by case reports and industry-funded studies; none show clinically meaningful benefit over oral supplementation or plain saline. FDA has issued multiple warning letters against IV therapy clinics for unapproved drug claims and manufacturing violations [23].

Texas HB 3749 (“Jenifer’s Law”), effective September 2025, tightened who can legally administer elective IV therapy in Texas following the 2023 death of Jenifer Cleveland at a Wortham, Texas med spa [24][26]. The subsequent investigation led to revocation of the supervising physician’s license and the 2023 passage of HB 3749, named in her memory.

Core HB 3749 requirements as interpreted by Texas health law practitioners [27]:

• PA/APRN administration only under physician supervision for elective IV therapy
• No RN-only IV bars without a PA/APRN on site or immediately available
• Written protocols and Good Faith Exam requirements
• Documentation standards tightened

If you’re considering IV therapy for “wellness” reasons, the evidence base doesn’t support it. If you have a documented deficiency, see an appropriate specialist. If you do use a Houston IV service, verify a PA/APRN is on site and a delegating physician has examined you.

Thyroid

Thyroid

Subclinical and clinical hypothyroidism are legitimate medical conditions. The standard treatment is levothyroxine titrated to normalize TSH — typically managed by primary care or endocrinology.

Many Houston wellness clinics market “thyroid optimization” — prescribing T3 (liothyronine), desiccated thyroid (Armour), or T3/T4 combinations to drive T3 levels above reference range for energy, metabolism, or weight loss. This approach has no evidence base for asymptomatic patients with normal TSH, carries risks of cardiac arrhythmia (atrial fibrillation), bone loss, and thyrotoxicosis, and is explicitly not recommended by the American Thyroid Association or Endocrine Society [31].

If you have fatigue, weight gain, and cold intolerance, get TSH, free T4, and TPO antibodies from a PCP or endocrinologist first. If your workup is normal, treating thyroid isn’t the answer — regardless of what a wellness consult tells you.

Texas Law

The Texas legal framework

Houston wellness medicine changed materially in 2025. Two developments matter most.

22 TAC Chapter 169, Subchapter E (effective January 9, 2025) replaced former §193.17 [25]. Key requirements for patients:

• Non-surgical medical cosmetic and wellness procedures — injectables (including hormone injections), IV therapy, laser, RF, HIFEM, compounded hormone administration — are the practice of medicine.
• A physician must delegate to qualified clinicians via signed written protocol.
• Good Faith Exam must be performed in person by an MD, DO, PA, or APRN before any treatment — an RN alone cannot perform the initial evaluation.
• A physician, PA, or APRN must be on-site or immediately available.
• Facilities must post the delegating physician’s name and Texas Medical License Number in public areas and treatment rooms.
• Prescriptive authority for controlled substances (testosterone is Schedule III) requires MD/DO or APRN with specific prescriptive authority agreement.
• Medical practices performing medical acts must be physician-owned (PLLC or PA). A non-physician-owned “wellness clinic” relying on a remote medical director is a textbook corporate practice of medicine risk.

HB 3749 (“Jenifer’s Law”) (effective September 2025) [24] tightened delegation and supervision specifically for IV therapy and IM injections in the med-spa context. Covered above.

Before you book anything involving an injection, infusion, or prescription at a Houston wellness clinic, confirm:

1. The delegating physician’s name and Texas Medical License Number is posted
2. A Good Faith Exam is performed by an MD, DO, PA, or APRN (not “an RN will evaluate you”)
3. The prescribing clinician holds appropriate state and DEA credentials for the substance being prescribed
4. The practice entity is physician-owned if it’s performing medical acts

What to Expect

Consultation, labs, monitoring

A legitimate first visit runs 45–60 minutes.

History. Complete medical history, current medications including OTC, pregnancy/planning status, family history of hormone-sensitive cancers, cardiovascular history, sleep apnea screening, depression/mood screening, substance use.

Labs vary by concern but typically include: CBC, CMP, lipid panel, fasting glucose + HbA1c, TSH + free T4, vitamin D, B12, ferritin. Women: add estradiol, FSH, progesterone (timing-dependent). Men: two morning fasting total testosterone (on separate days), free testosterone, SHBG, LH, FSH, PSA (age 40+), estradiol. GLP-1 candidates: add fasting insulin, comprehensive metabolic panel, and MTC/MEN2 family-history screen.

Physical exam. Appropriate to concern. TRT requires GU exam and PSA discussion. HRT should include breast exam and appropriate screening status (mammogram, pap).

Monitoring. TRT: 6-week and 12-week post-initiation labs, then quarterly year 1, then every 6 months. HRT: annual review minimum, symptom-driven dose adjustment. GLP-1: monthly during titration, quarterly thereafter, plus comorbidity labs. Pellet therapy: 6-week post-insertion level checks (often skipped in commercial practice).

A clinic that doesn’t require baseline labs before prescribing hormones or GLP-1s is not practicing medicine. It’s selling products.

Houston Pricing

Houston pricing in 2026

All pricing from verified Houston provider websites and manufacturer direct channels, accessed April 2026.

How to Choose

How to choose a provider — and red flags to watch

Credentials first.

• Is the practice physician-owned (PLLC or PA)? If it’s an LLC with a remote MD, that’s a corporate-practice-of-medicine red flag.
• Is the delegating physician’s name and Texas Medical License Number posted?
• Is your initial evaluation performed in person by an MD, DO, PA, or APRN (not RN-only)?
• For HRT specifically — does the practice have a gynecologist, endocrinologist, or Menopause Society Certified Practitioner on the team?

Monitoring rigor.

• Do they require baseline labs before prescribing? If not, walk away.
• For TRT: do they require two morning fasting total testosterone measurements plus secondary workup, or single-lab prescribing?
• For HRT: do they discuss transdermal over oral and risks appropriate to your profile, or default everyone to pellets?
• For GLP-1: do they measure baseline fasting glucose, HbA1c, insulin, comprehensive metabolic panel, or just “let’s start semaglutide today”?

Product sourcing.

• GLP-1s: manufacturer-sourced (LillyDirect, NovoCare, or pharmacy-dispensed brand) vs. compounded. Compounded at scale in 2026 is a gray-zone indicator [14][15].
• HRT: FDA-approved vs. compounded. If compounded, is there a documented patient-specific reason?
• Peptides: any Category-2 peptide being offered (BPC-157, CJC/ipamorelin, TB-500, thymosin alpha-1 injectable) is legally prohibited [21].

Red flags — walk away:

• No delegating physician or Texas Medical License Number posted
• Initial evaluation by RN only (violates 22 TAC Chapter 169 Subchapter E)
• Pellet-first protocols without discussion of FDA-approved transdermal alternatives
• TRT on a single lab with no secondary workup
• Compounded semaglutide/tirzepatide at commodity pricing (post-shortage-resolution gray zone)
• Any Category-2 peptides on the menu
• RN-run IV bars without PA/APRN on site (post-Jenifer’s Law violation)
• Thyroid T3 prescribed to patients with normal TSH
• Same-day prescribing with no lab workup
• Long-term contracts required before first labs return